COST-EFFECTIVENESS ASSESSMENT OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV20) AMONG OLDER ADULTS IN THE PHILIPPINES
Author(s)
Mica Anna Borcena Policarpio, RPh1, Winniefer Nua, MS2, Jecyll Dayanghirang, MD1, Ervin Cheong, MS3, Ahuva Averin, MPP4, Anu Suokas, PhD5, Mark Atwood, MS6, Liping Huang, MD, MS7.
1Pfizer, Inc., Manila, Philippines, 2Pfizer, In., Manila, Philippines, 3Pfizer Singapore LTD, Singapore, Singapore, 4Consultant IV, Avalere Health, Washington, DC, USA, 5Avalere Health, London, United Kingdom, 6Avalere Health, Washington, DC, USA, 7Pfizer, Washington Crossing, PA, USA.
1Pfizer, Inc., Manila, Philippines, 2Pfizer, In., Manila, Philippines, 3Pfizer Singapore LTD, Singapore, Singapore, 4Consultant IV, Avalere Health, Washington, DC, USA, 5Avalere Health, London, United Kingdom, 6Avalere Health, Washington, DC, USA, 7Pfizer, Washington Crossing, PA, USA.
OBJECTIVES: Publicly funded pneumococcal vaccination for older adults in Philippines comprises two doses of 23-valent pneumococcal polysaccharide vaccine (PPV23; PPV23+PPV23), whereas sequential vaccination with 13-valent pneumococcal conjugate vaccine (PCV13) and PPV23 (PCV13→PPV23) is used in private healthcare settings. We evaluated the cost-effectiveness of single-dose 20-valent PCV (PCV20) versus PPV23+PPV23 in adults aged ≥60 years from the government perspective and PCV13→PPV23 in adults aged ≥50 years from the private perspective.
METHODS: A Markov-cohort model projected lifetime cases, deaths, and costs associated with invasive pneumococcal disease (IPD) and non-bacteremic pneumococcal pneumonia (NBPP). Philippines-specific epidemiologic and cost inputs were employed where available. Vaccine uptake at model entry was 52.9% in government settings and 17.4% in private healthcare settings, with 100% completion of the subsequent dose (PPV23) in multi-dose strategies. Cost-effectiveness (cost per quality‑adjusted life‑year [QALY] gained) was assessed using willingness-to-pay (WTP) threshold of 1XPhilippine gross domestic product per capita (PHP230,494; discounting=7%/year). Probabilistic sensitivity analyses (1,000 simulations) were performed.
RESULTS: In both perspectives, PCV20 was dominant (i.e., less costly and more effective) compared to existing strategies. From the government perspective among adults aged ≥60 years, PCV20 prevented 10,354 cases of IPD and NBPP and 1,551 deaths, yielded 3,703 QALYs, and saved PHP175 million. From the private perspective among adults aged ≥50 years, PCV20 prevented 3,639 cases of IPD and NBPP and 514 deaths, yielded 1,673 QALYs, and saved PHP2,421 million. In probabilistic sensitivity analysis, PCV20 was dominant in 100% of simulations from both government and private payer perspectives.
CONCLUSIONS: Replacing current pneumococcal vaccination strategies for older adults in the Philippines with a single dose of PCV20 would improve health outcomes while reducing total healthcare costs. PCV20 offers programmatic advantages and may potentially encourage higher vaccine uptake.
METHODS: A Markov-cohort model projected lifetime cases, deaths, and costs associated with invasive pneumococcal disease (IPD) and non-bacteremic pneumococcal pneumonia (NBPP). Philippines-specific epidemiologic and cost inputs were employed where available. Vaccine uptake at model entry was 52.9% in government settings and 17.4% in private healthcare settings, with 100% completion of the subsequent dose (PPV23) in multi-dose strategies. Cost-effectiveness (cost per quality‑adjusted life‑year [QALY] gained) was assessed using willingness-to-pay (WTP) threshold of 1XPhilippine gross domestic product per capita (PHP230,494; discounting=7%/year). Probabilistic sensitivity analyses (1,000 simulations) were performed.
RESULTS: In both perspectives, PCV20 was dominant (i.e., less costly and more effective) compared to existing strategies. From the government perspective among adults aged ≥60 years, PCV20 prevented 10,354 cases of IPD and NBPP and 1,551 deaths, yielded 3,703 QALYs, and saved PHP175 million. From the private perspective among adults aged ≥50 years, PCV20 prevented 3,639 cases of IPD and NBPP and 514 deaths, yielded 1,673 QALYs, and saved PHP2,421 million. In probabilistic sensitivity analysis, PCV20 was dominant in 100% of simulations from both government and private payer perspectives.
CONCLUSIONS: Replacing current pneumococcal vaccination strategies for older adults in the Philippines with a single dose of PCV20 would improve health outcomes while reducing total healthcare costs. PCV20 offers programmatic advantages and may potentially encourage higher vaccine uptake.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE753
Topic
Economic Evaluation
Disease
Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory), Vaccines